Fatostatin NEW
| Price | $30 | $43 | $67 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Fatostatin | CAS No.: 125256-00-0 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Fatostatin |
| Description | Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. |
| In vitro | Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells[1]. Fatostatin (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells[2]. |
| In vivo | Fatostatin (30 mg/kg; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 70 mg/mL (237.76 mM) H2O : Insoluble Ethanol : 70 mg/mL (237.76 mM) |
| Keywords | mice | 125B11 | prostate | cancer | Fatty Acid Synthase (FASN) | gene | human | insulin-induced | ob/ob | inhibit | expression | Golgi | Inhibitor | Fatostatin | adipogenesis | SREBP-mediated |
| Inhibitors Related | MSU-42011 | Dehydrocholate sodium | Ethyl phenylglyoxylate | Pyrazinamide | A-769662 | Orlistat | trans-Chalcone | TVB-3664 | L-Carnitine | Probucol | Lycorine | Fenipentol |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-08-29 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY